The Prader-Willi syndrome (PWS) therapeutic market is entering a new era, driven by innovation and increasing demand for more effective treatments. While Soleno’s VYKAT XR has become a cornerstone therapy for addressing hyperphagia and metabolic symptoms, a growing list of drug candidates are set to reshape the treatment landscape. Notably, molecules like Carbetocin,...